Cost-benefit analysis of a pharmacist-advocated pneumococcal vaccination program

V. N. Joish, M. R M T Limcangco, Edward P Armstrong

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Pharmacists are increasingly taking on immunization roles in their communities as advocates, facilitators, and immunizers. Between 50% and 94% of people who receive a pharmacist's recommendation to be immunized accept that recommendation. Pneumococcal diseases impose a heavy burden on the health of adults in developed and developing countries. There are sound reasons for believing that much of this burden could be reduced by widespread use of the current pneumococcal vaccine. This month's column presents a cost-benefit analysis, using both published and hypothetical figures, to compare a traditional pneumococcal vaccination program with one that uses pharmacists as advocates for pneumococcal vaccination.

Original languageEnglish (US)
Pages (from-to)147-156
Number of pages10
JournalFormulary
Volume36
Issue number2
StatePublished - 2001
Externally publishedYes

Fingerprint

Pharmacists
Cost-Benefit Analysis
Vaccination
Pneumococcal Vaccines
Developed Countries
Developing Countries
Immunization
Health

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Cost-benefit analysis of a pharmacist-advocated pneumococcal vaccination program. / Joish, V. N.; Limcangco, M. R M T; Armstrong, Edward P.

In: Formulary, Vol. 36, No. 2, 2001, p. 147-156.

Research output: Contribution to journalArticle

Joish, V. N. ; Limcangco, M. R M T ; Armstrong, Edward P. / Cost-benefit analysis of a pharmacist-advocated pneumococcal vaccination program. In: Formulary. 2001 ; Vol. 36, No. 2. pp. 147-156.
@article{9ded409461b1493484fa55a9c7576675,
title = "Cost-benefit analysis of a pharmacist-advocated pneumococcal vaccination program",
abstract = "Pharmacists are increasingly taking on immunization roles in their communities as advocates, facilitators, and immunizers. Between 50{\%} and 94{\%} of people who receive a pharmacist's recommendation to be immunized accept that recommendation. Pneumococcal diseases impose a heavy burden on the health of adults in developed and developing countries. There are sound reasons for believing that much of this burden could be reduced by widespread use of the current pneumococcal vaccine. This month's column presents a cost-benefit analysis, using both published and hypothetical figures, to compare a traditional pneumococcal vaccination program with one that uses pharmacists as advocates for pneumococcal vaccination.",
author = "Joish, {V. N.} and Limcangco, {M. R M T} and Armstrong, {Edward P}",
year = "2001",
language = "English (US)",
volume = "36",
pages = "147--156",
journal = "Formulary",
issn = "1082-801X",
publisher = "Advanstar Communications",
number = "2",

}

TY - JOUR

T1 - Cost-benefit analysis of a pharmacist-advocated pneumococcal vaccination program

AU - Joish, V. N.

AU - Limcangco, M. R M T

AU - Armstrong, Edward P

PY - 2001

Y1 - 2001

N2 - Pharmacists are increasingly taking on immunization roles in their communities as advocates, facilitators, and immunizers. Between 50% and 94% of people who receive a pharmacist's recommendation to be immunized accept that recommendation. Pneumococcal diseases impose a heavy burden on the health of adults in developed and developing countries. There are sound reasons for believing that much of this burden could be reduced by widespread use of the current pneumococcal vaccine. This month's column presents a cost-benefit analysis, using both published and hypothetical figures, to compare a traditional pneumococcal vaccination program with one that uses pharmacists as advocates for pneumococcal vaccination.

AB - Pharmacists are increasingly taking on immunization roles in their communities as advocates, facilitators, and immunizers. Between 50% and 94% of people who receive a pharmacist's recommendation to be immunized accept that recommendation. Pneumococcal diseases impose a heavy burden on the health of adults in developed and developing countries. There are sound reasons for believing that much of this burden could be reduced by widespread use of the current pneumococcal vaccine. This month's column presents a cost-benefit analysis, using both published and hypothetical figures, to compare a traditional pneumococcal vaccination program with one that uses pharmacists as advocates for pneumococcal vaccination.

UR - http://www.scopus.com/inward/record.url?scp=0035101976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035101976&partnerID=8YFLogxK

M3 - Article

VL - 36

SP - 147

EP - 156

JO - Formulary

JF - Formulary

SN - 1082-801X

IS - 2

ER -